NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free XBIO Stock Alerts $3.77 -0.21 (-5.28%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.77▼$3.9050-Day Range$3.27▼$4.3552-Week Range$2.55▼$5.97Volume3,449 shsAverage Volume7,374 shsMarket Capitalization$5.81 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Xenetic Biosciences alerts: Email Address Xenetic Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside961.0% Upside$40.00 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.43) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 stars 3.0 Analyst's Opinion Consensus RatingXenetic Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Xenetic Biosciences has a forecasted upside of 961.0% from its current price of $3.77.Amount of Analyst CoverageXenetic Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently decreased by 74.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XBIO. Previous Next 3.3 News and Social Media Coverage News SentimentXenetic Biosciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Xenetic Biosciences this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by InstitutionsOnly 15.12% of the stock of Xenetic Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xenetic Biosciences are expected to grow in the coming year, from ($3.43) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Xenetic Biosciences Stock (NASDAQ:XBIO)Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More XBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIO Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comXenetic Biosciences Inc (NASDAQ:XBIO) Short Interest UpdateMarch 25, 2024 | americanbankingnews.comBrokers Set Expectations for Xenetic Biosciences Inc's Q1 2024 Earnings (NASDAQ:XBIO)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | americanbankingnews.comXenetic Biosciences (NASDAQ:XBIO) vs. Akero Therapeutics (NASDAQ:AKRO) Head to Head AnalysisMarch 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… January 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastNovember 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformMarch 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesFebruary 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersSee More Headlines Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Price Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+961.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,140,000.00 Net Margins-162.84% Pretax Margin-162.79% Return on Equity-36.43% Return on Assets-33.74% Debt Debt-to-Equity RatioN/A Current Ratio11.84 Quick Ratio11.84 Sales & Book Value Annual Sales$2.54 million Price / Sales2.29 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.59Miscellaneous Outstanding Shares1,540,000Free Float1,402,000Market Cap$5.81 million OptionableNot Optionable Beta2.61 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsEnsysce BiosciencesNASDAQ:ENSCNexImmuneNASDAQ:NEXIYumanity TherapeuticsNASDAQ:YMTXKinetaNASDAQ:KAPulmatrixNASDAQ:PULMView All Competitors XBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Xenetic Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares. View XBIO analyst ratings or view top-rated stocks. What is Xenetic Biosciences' stock price target for 2024? 1 brokerages have issued 1 year target prices for Xenetic Biosciences' stock. Their XBIO share price targets range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 961.0% from the stock's current price. View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts. How have XBIO shares performed in 2024? Xenetic Biosciences' stock was trading at $3.45 at the beginning of the year. Since then, XBIO shares have increased by 9.3% and is now trading at $3.77. View the best growth stocks for 2024 here. Are investors shorting Xenetic Biosciences? Xenetic Biosciences saw a decline in short interest in March. As of March 15th, there was short interest totaling 2,200 shares, a decline of 74.7% from the February 29th total of 8,700 shares. Based on an average trading volume of 5,300 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the company's stock are short sold. View Xenetic Biosciences' Short Interest. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.10. The firm earned $0.35 million during the quarter, compared to analysts' expectations of $0.20 million. Xenetic Biosciences had a negative net margin of 162.84% and a negative trailing twelve-month return on equity of 36.43%. When did Xenetic Biosciences' stock split? Xenetic Biosciences's stock reverse split on the morning of Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). Who are Xenetic Biosciences' major shareholders? Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.